The Max Foundation and Tanner Pharma partner on innovative drug distribution model
The Max Foundation and Tanner Pharma Group have partnered to create an innovative distribution model to deliver oncology products to patients in need.
Solidarity Fund Celebrates First Delivery
Earlier this month, The Max Foundation celebrated the delivery of 110 BCR-ABL molecular tests to Mercy Medical Center Cambodia. The delivery was the first of its kind for Max, made possible through our 2018 Diagnostics Solidarity Fund. Two more deliveries – one to Kyrgyzstan and one to Bolivia – are in process now, and we’re hopeful there will be many more to come.
Why are BCR-ABL molecular tests important?
Before a patient can be treated, he or she must first be diagnosed. A simple concept to be sure, but with a disease like chronic myeloid leukemia (CML), diagnosis isn’t that simple.
In order to accurately diagnose CML and monitor a patient’s ongoing treatment, molecular testing is required to determine the presence and prevalence of the mutated BCR-ABL protein. However, in the low- and middle-income countries where we work, molecular testing is often unavailable or prohibitively expensive.
Bridging Gaps in Access
To help bridge that gap for patients, we established the 2018 Diagnostics Solidarity Fund – a donation program dedicated to increasing access to molecular testing in 22 resource-challenged countries. Specifically, the fund enables The Max Foundation to donate up to 3,600 BCR-ABL molecular tests to qualifying institutions.
Each one of the 110 tests delivered to Mercy Medical Center Cambodia represents an opportunity – either for a new patient to gain access to life-saving treatment, or, for an existing patient to improve his or her disease outcome. Those are opportunities worth celebrating.
Special Thanks
We offer our heartfelt thanks and appreciation to the CML/GIST team at Mercy Medical Cambodia: Drs. Tim Benadum, Mary Kluck, Inge Mathes, and Alan Norman, as well as head administrator Sovatdy Sanh, and laboratory technicians Kanhara Im and Saora Toeur (pictured). They go above and beyond for their patients each and every day and it’s an honor to support their efforts.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Related Articles
The Critical Role of Humanitarian Donations
In a recent commentary published in the Journal of Global Oncology, co-authors Pat Garcia-Gonzalez MA, Gilberto Lopes MD, Erin Schwartz and Lawrence Shulman MD, clearly outline the need and efficacy of humanitarian donation programs using lessons learned from the success of joint access initiatives between Novartis and The Max Foundation.
New study confirms an excellent survival rate of cancer patients in a medication donation program
A new study led by Boston University School of Public Health, The Max Foundation, and Novartis Oncology found that chronic myeloid leukemia (CML) patients taking first-line treatment in low- and middle-income countries (LMICs) as part of the Glivec International Patient Assistance Program (GIPAP) have survival rates that compare favorably to those of CML patients receiving treatment in high-income countries.